Tenofovir Disoproxil Fumarate Improves Outcomes Following Palliative Transarterial Chemoembolization for Hepatitis B Virus Related Hepatocellular Carcinoma

Trial Profile

Tenofovir Disoproxil Fumarate Improves Outcomes Following Palliative Transarterial Chemoembolization for Hepatitis B Virus Related Hepatocellular Carcinoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Antineoplastics
  • Indications Hepatitis B; Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top